• Publications
  • Influence
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well asExpand
  • 810
  • 63
  • PDF
Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis
Objectives To propose an improvement on the current classification of renal dysfunction in cirrhosis. Clinicians caring for patients with cirrhosis recognize that the development of renal dysfunctionExpand
  • 311
  • 31
  • PDF
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome
Hepatorenal syndrome (HRS) is a functional renal disorder complicating decompensated cirrhosis. Treatments to date, except liver transplantation, have been able to improve but not normalize renalExpand
  • 319
  • 15
A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial
Hyponatremia in advanced cirrhosis and ascites or congestive heart failure (CHF) is the result of an inappropriate increase in vasopressin secretion, which acts through activation of specific V2Expand
  • 278
  • 14
Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group
IntroductionRenal dysfunction is a common complication in patients with end-stage cirrhosis. Since the original publication of the definition and diagnostic criteria for the hepatorenal syndromeExpand
  • 124
  • 13
  • PDF
Recent advances in our understanding of hepatorenal syndrome
  • F. Wong
  • Medicine
  • Nature Reviews Gastroenterology &Hepatology
  • 22 May 2012
Hepatorenal syndrome (HRS) is a serious complication of advanced cirrhosis with ascites. HRS develops as a result of abnormal haemodynamics, leading to splanchnic and systemic vasodilatation, butExpand
  • 81
  • 13
The North American Study for the Treatment of Refractory Ascites.
BACKGROUND AND AIMS The clinical utility of transjugular intrahepatic portosystemic shunts (TIPS) vis-à-vis total paracentesis in the management of refractory ascites is unclear. METHODS AExpand
  • 357
  • 11
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis
Ascites is a frequent complication of cirrhosis and portal hypertension, because of the increase of the sinusoidal hydrostatic pressure. Cirrhosis accounts for over 75% of episodes of ascites.Expand
  • 132
  • 11
The Use of E/A Ratio as a Predictor of Outcome in Cirrhotic Patients Treated With Transjugular Intrahepatic Portosystemic Shunt
OBJECTIVES:The clinical significance of diastolic dysfunction in cirrhosis, a feature of cirrhotic cardiomyopathy, is unclear. The aim of this study was to assess the utility of E/A ratio, anExpand
  • 148
  • 11
Hyponatremia in cirrhosis: Results of a patient population survey
Low serum sodium concentration is an independent predictor of mortality in patients with cirrhosis, but its prevalence and clinical significance is unclear. To evaluate prospectively the prevalenceExpand
  • 319
  • 9